EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide

Kevin Doello, Maria Angeles Chico, Francisco Quiñonero iD, Raúl Ortiz, Jose Prados iD, Cristina Mesas, Consolación Melguizo iD

Medicina · 2024

DOI: 10.3390/medicina60071039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicina, 2024. Verfasst von Kevin Doello und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Service, Virgen de las Nieves Hospital, 18014 Granada, Spain. Hauptthemen laut MEDLINE: Octreotide, Neuroendocrine Tumors, Antineoplastic Agents, Hormonal, Receptors, Somatostatin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: High-grade malignant neuroendocrine tumors (G3 NETs) and neuroendocrine carcinomas (NECs) are characterized by rapid proliferation, high metastatic capacity, and strong expression of somatostatin receptors (SSTRs). We aimed to analyze the presence of SSTRs in NET G3 and NEC, and to correlate their expression with the use of octreotide and pasireotide. Materials and Methods: For this purpose, we first performed a retrospective study of G3 NET and NEC patients, which included the determination of SSTR expression and response to octreotide treatment. Second, we selected the H69 small cell lung cancer cell line to determine the effect of octreotide and pasireotide.

Results

Our results showed the traditional somatostatin analog (SSA) octreotide was ineffective in patients with NET G3 and NEC. On the other hand, RT-qPCR showed a high expression of SSTR2 and SSTR5 in H69 cells. Interestingly, while octreotide did not modify H69 cell proliferation, a strong inhibition of proliferation was detected with the use of pasireotide.

Conclusions

In view of these results, a clinical trial in NET G3 and NEC patients using pasireotide is necessary to determine the usefulness of this drug in improving patient treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OctreotideNeuroendocrine TumorsAntineoplastic Agents, HormonalReceptors, SomatostatinSomatostatinCell ProliferationHormonesMaleFemaleMiddle AgedAgedTreatment OutcomeHumans

Stichwörter der Autor:innen

carcinomaneuroendocrine tumorspasireotidesomatostatin receptors

Substanzen

OctreotideAntineoplastic Agents, HormonalReceptors, SomatostatinpasireotideSomatostatinHormones

Autor:innen und Institutionen

  • Medical Oncology Service, Virgen de las Nieves Hospital, 18014 Granada, Spain.
  • Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18014 Granada, Spain.
  • Institute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), 18100 Granada, Spain.
  • Department of Anatomy and Embryology, University of Granada, 18071 Granada, Spain.

ORCID-Profile: Francisco Quiñonero, Jose Prados, Consolación Melguizo

Zitieren

APA

Doello, K., Chico, M. A., Quiñonero, F., Ortiz, R., Prados, J., Mesas, C., & Melguizo, C. (2024). Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide. Medicina. https://doi.org/10.3390/medicina60071039

Vancouver

Doello K, Chico MA, Quiñonero F, Ortiz R, Prados J, Mesas C, et al. Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide. Medicina. 2024. doi:10.3390/medicina60071039

BibTeX
@article{Doello2024,
  author = {Doello, Kevin and Chico, Maria Angeles and Quiñonero, Francisco and Ortiz, Raúl and Prados, Jose and Mesas, Cristina and Melguizo, Consolación},
  title = {Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide},
  journal = {Medicina},
  year = {2024},
  doi = {10.3390/medicina60071039}
}
Kostenlos starten →